TranS1 Inc. Reports Operating Results for the Fourth Quarter of 2009

Share this story with your network

Highlights:

Fourth quarter revenues were $6.3 million

674 TranS1 procedures performed globally in the quarter

Gross margin was 79.9% for the quarter

GAAP loss per share was $0.28 for the quarter

Non-GAAP loss per share was $0.25 for the quarter

WILMINGTON, N.C., Feb. 23, 2010 (GLOBE NEWSWIRE) — TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine, today announced its financial results for the fourth quarter ended December 31, 2009.

Revenues were $6.3 million in the fourth quarter of 2009, representing a 15% decrease over revenues of $7.4 million in the fourth quarter of 2008. Gross margin was 79.9% in the fourth quarter of 2009 as compared to 84.6% in the fourth quarter of 2008.

Operating expenses were $10.7 million in the fourth quarter of 2009 compared to $11.1 million in the fourth quarter of 2008. The decrease in operating expenses is primarily attributable to a decrease in sales and marketing costs as a result of the decreased commissions due to lower sales, partially offset by increased spending for research and development.

Net loss was $5.7 million and $4.5 million for the quarters ended December 31, 2009 and 2008, respectively.   GAAP net loss per common share was $0.28 in the fourth quarter of 2009 compared to a net loss per share of $0.22 in the fourth quarter of 2008.

For the quarters ended December 31 2009 and 2008, on a non-GAAP basis adjusting for non-cash stock compensation expense, net loss per common share was $0.25 and $0.20, respectively.

Cash, cash-equivalents and investments were $55.3 million as of December 31, 2009.

“Our results this quarter, and for much of 2009, were impacted by concerns in the marketplace surrounding reimbursement for our AxiaLIF procedure. We are using the experience we gained in 2009 to better educate and support our current and prospective surgeon users as they navigate the current reimbursement landscape,” said Rick Randall, CEO of TranS1. “We are approaching 2010 with a leaner, more experienced sales force armed with a broader product offering to expand our clinical indications within the lumbar spine.”

Conference Call

TranS1 will host a conference call today at 4:30 pm ET to discuss its fourth quarter financial results. To listen to the conference call on your telephone, please dial (877) 881-2183 for domestic callers and (970) 315-0453 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or the archived recording, use the following link at http://ir.trans1.com/events.cfm.

Non-GAAP Measures

Management uses certain non-GAAP financial measures such as non-GAAP net loss and net loss per share, which exclude stock based compensation. This non-GAAP presentation is given in part to enhance the understanding of the company’s historical financial performance and comparability between periods. The company believes that the non-GAAP presentation to exclude stock-based compensation is relevant and useful information that will be widely used by investors and analysts. Accordingly, the company is disclosing this information to permit additional analysis of the company’s performance. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. A reconciliation of the GAAP financial measures to the comparable non-GAAP financial measure is included below.

About TranS1 Inc.

TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine. TranS1 currently markets the AxiaLIF family of products for single and multilevel lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion.  TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.

Forward-Looking Statements

This press release includes forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. These risks and uncertainties include, among other things, risks associated with the adoption of a new technology by spine surgeons, product development efforts, regulatory requirements, maintenance and prosecution of adequate intellectual property protection and other economic and competitive factors. These forward looking statements are based on the company’s expectations as of the date of this press release and the company undertakes no obligation to update information provided in this press release. For a discussion of risks and uncertainties associated with TranS1’s business, please review the company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2008.

TranS1 Inc.
Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended
Dec. 31,
Twelve Months Ended
Dec. 31,
2009 2008 2009 2008
Revenue $ 6,279 $ 7,354 $ 29,807 $ 25,304
Cost of revenue 1,264 1,129 5,687 4,315
Gross profit 5,015 6,225 24,120 20,989
Operating expenses:
Research and development 1,392 839 6,439 4,081
Sales and marketing 7,878 8,696 34,098 29,375
General and administrative 1,471 1,554 7,184 7,116
Total operating expenses 10,741 11,089 47,721 40,572
Operating loss (5,726) (4,864) (23,601) (19,583)
Interest income 23 331 405 2,548
Net loss $ (5,703) $ (4,533) $ (23,196) $ (17,035)
Net loss per common share – basic and diluted $ (0.28) $ (0.22) $ (1.13) $ (0.84)
Weighted average common shares outstanding – basic and diluted 20,641 20,534 20,604 20,289
Stock-based compensation is included in operating
expenses in the following categories:
Cost of revenue $ 19 $ 21 $ 74 $ 66
Research and development 45 18 186 412
Sales and marketing 338 154 1,481 1,474
General and administrative 198 189 1,058 1,027
$ 600 $ 382 $ 2,799 $ 2,979
Reconciliation of Quarterly Results
(in thousands, except per share amounts)
(Unaudited) 2009 2008
GAAP net loss $ (5,703) $ (4,533)
Stock based compensation 600 382
Non-GAAP net loss $ (5,103) $ (4,151)
Shares used in computing GAAP and non-GAAP loss per share 20,641 20,534
Non-GAAP loss per share $ (0.25) $ (0.20)
Reconciliation of Year-To-Date Results
(in thousands, except per share amounts)
(Unaudited) 2009 2008
GAAP net loss $ (23,196) $ (17,035)
Stock based compensation 2,799 2,979
Non-GAAP net loss $ (20,397) $ (14,056)
Shares used in computing GAAP and non-GAAP loss per share 20,604 20,289
Non-GAAP loss per share $ (0.99) $ (0.69)
TranS1 Inc.
Balance Sheets
(in thousands)
(Unaudited)
December 31, December 31,
2009 2008
Assets
Current assets:
Cash and cash equivalents $ 29,298 $ 42,051
Short-term investments 25,953 35,215
Accounts receivable, net 3,926 4,812
Inventory 7,325 6,369
Prepaid expenses and other assets 676 632
Total current assets 67,178 89,079
Property and equipment, net 1,813 1,412
Total assets $ 68,991 $ 90,491
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 2,442 $ 2,896
Accrued expenses 1,269 2,009
Total current liabilities 3,711 4,905
Stockholders’ equity
Common stock 2 2
Additional paid-in capital 136,402 133,507
Accumulated other comprehensive income (5)
Accumulated deficit (71,119) (47,923)
Total stockholders’ equity 65,280 85,586
Total liabilities and stockholders’ equity $ 68,991 $ 90,491
TranS1 Inc.
Statements of Cash Flows
(in thousands)
(Unaudited)
Twelve Months Ended Dec. 31,
2009 2008
Cash flows from operating activities:
Net loss $ (23,196) $ (17,035)
Adjustments to reconcile net loss to net
cash used in operating activities
Depreciation 909 804
Stock-based compensation 2,799 2,979
Allowance for excess and obsolete inventory 505 400
Provision for bad debts 80 101
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable 806 (1,688)
(Increase) decrease in inventory (1,461) (2,744)
(Increase) decrease in prepaid expenses (44) (35)
Increase (decrease) in accounts payable (454) 1,265
Increase (decrease) in accrued expenses (740) 223
Net cash used in operating activities (20,796) (15,730)
Cash flows from investing activities:
Purchase of property and equipment (1,310) (1,128)
Purchases of investments (50,872) (55,761)
Sales and maturities of short-term investments 60,134 49,791
Net cash provided by (used in) investing activities 7,952 (7,098)
Cash flows from financing activities:
Proceeds from issuance of common stock 91 203
Net cash provided by (used in) financing activities 91 203
Net decrease in cash and cash equivalents (12,753) (22,625)
Cash and cash equivalents, beginning of period 42,051 64,676
Cash and cash equivalents, end of period $ 29,298 $ 42,051
CONTACT:  TranS1 Inc.
          Investors:
          Michael Luetkemeyer, Chief Financial Officer
          910-332-1700

          Westwicke Partners
          Mark Klausner
          443-213-0501
          mark.klausner@westwicke.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*